SCHEMBL2656486

SCHEMBL2656486

Cc1[nH]cc(C(=O)O)c(=O)c1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 5/20 0.45
PIM3 Q86V86 2/20 0.45
CLK4 Q9HAZ1 1/20 0.45
CSNK2A2 P19784 4/20 0.44
CSNK2B P67870 4/20 0.44
NOTUM Q6P988 2/20 0.42
KDM4E B2RXH2 4/20 0.40
HPGD P15428 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 2/20 0.39
CYP1A2 P05177 2/20 0.39
KDM3B Q7LBC6 1/20 0.39
GAA P10253 1/20 0.39
PIM1 P11309 1/20 0.38
MEN1 O00255 1/20 0.36
ALOX12 P18054 1/20 0.36
KMT2A Q03164 1/20 0.36
DNA2 P51530 1/20 0.36
CASP6 P55212 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1145646 0.83 ALDH1A1 (0.37) CSNK2A1PIM3CLK4CSNK2A2CSNK2B
SCHEMBL15491101 0.80 CSNK2A1 (0.50) CSNK2A1PIM3CLK4CSNK2A2CSNK2B
SCHEMBL28346251 0.78 CSNK2A1 (0.41) CSNK2A1PIM3CLK4CSNK2A2CSNK2B
SCHEMBL2933319 0.77 CSNK2A1 (0.45) CSNK2A1PIM3CLK4CSNK2A2CSNK2B
SCHEMBL1146532 0.77 CSNK2A1 (0.45) CSNK2A1PIM3CLK4CSNK2A2CSNK2B
SCHEMBL755293 0.74 KDM4E (0.48) CSNK2A1PIM3CLK4CSNK2A2CSNK2B
SCHEMBL547358 0.73 NOTUM (0.50) CSNK2A1PIM3CLK4CSNK2A2CSNK2B
SCHEMBL10462527 0.72 CSNK2A1 (0.47) CSNK2A1PIM3CLK4CSNK2A2CSNK2B
SCHEMBL2804501 0.71 NOTUM (0.65) CSNK2A1PIM3CLK4CSNK2A2CSNK2B
SCHEMBL28944544 0.69 NOTUM (0.50) CSNK2A1PIM3CLK4CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371428-B2 Pyridone compounds and methods of use EXELIXIS, INC. (US) 2025-07-29 US disclosed
WO-2023155886-A1 PYRAZOLOPYRIDINE COMPOUNDS AS TAM INHIBITORS SHANGHAI ANTENGENE CORPORATION LIMITED (CN) 2023-08-24 WO disclosed
WO-2023051464-A1 PYRAZOLOPYRIDINE COMPOUNDS AS TAM INHIBITORS SHANGHAI ANTENGENE CORPORATION LIMITED (CN) 2023-04-06 WO disclosed
US-20220315579-A1 PYRIDONE COMPOUNDS AND METHODS OF USE EXELIXIS, INC. 2022-10-06 US disclosed
EP-4034532-A1 PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE Exelixis, Inc. (US) 2022-08-03 EP disclosed
CN-114787144-A Pyridone compounds and methods for modulating protein kinases 埃克塞里艾克西斯公司 2022-07-22 CN disclosed
WO-2021062245-A1 PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE EXELIXIS, INC. (US) 2021-04-01 WO disclosed
US-RE46630-E1 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity BOEHRINGER INGELHELHEIM INTERNATIONAL GMBH (DE) 2017-12-12 US disclosed
US-RE46630-E1 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity BOEHRINGER INGELHELHEIM INTERNATIONAL GMBH (DE) 2017-12-12 US disclosed
US-RE46630-E1 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity BOEHRINGER INGELHELHEIM INTERNATIONAL GMBH (DE) 2017-12-12 US disclosed
US-20140057916-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-27 US disclosed
WO-2014029832-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-27 WO disclosed
US-20140057926-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-27 US disclosed
US-20140057916-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-27 US disclosed
US-20140057920-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-27 US disclosed
EP-2229377-A1 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS Wyeth LLC (US) 2010-09-22 EP disclosed
WO-2009076602-A1 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS WYETH (US) 2009-06-18 WO disclosed
US-6333336-B1 GAMMA-AMINOBUTYRIC ACID RECEPTORS AS ANTICONVULSANTS FORMING THE COMPOUND BY AMIDATION MERCK SHARP & DOHME LTD. (GB) 2001-12-25 US disclosed
EP-1064283-A1 PYRAZOLO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2001-01-03 EP disclosed
WO-1999048892-A1 PYRAZOLO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057920-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY SERPINB1, ELANE, SERPINB6 CSNK2A1 2511/4885PIM3 4668/4885CLK4 3954/4885
US-20140057926-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY SERPINB1, ELANE, SERPINB6 CSNK2A1 2511/4885PIM3 4668/4885CLK4 3954/4885
US-12371428-B2 Pyridone compounds and methods of use PDXK, PLK2, MAP4K2 CSNK2A1 302/4885PIM3 1059/4885CLK4 518/4885
US-20140057916-A1 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY SERPINB1, ELANE, SERPINB6 CSNK2A1 2511/4885PIM3 4668/4885CLK4 3954/4885
US-20220315579-A1 PYRIDONE COMPOUNDS AND METHODS OF USE PDXK, PLK2, MAP4K2 CSNK2A1 302/4885PIM3 1059/4885CLK4 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.